Elkhart Memorial came in riding a high Friday night at The Rock. Their record was 7-1 and ranked #5 in the 4A poll. But the Pilgrims forgot to read the Crimson Charger press clippings as they took down Memorial 61-57 in overtime.
The game was tight throughtout the NLC contest. Memorial took a one point lead after one period. The score was tied at halftime, at the end of the third quarter, and at the end of regulation 48-48.
Both teams had opportunities to gain an upper hand in regulation, but each time one team looked to be making a run, the other team battled back to tie the game. The difference ended up being at the free throw line. The Pilgrims hit 16-25 while Memorial was only able to can 8-14. Joe Barron, Adam Hunter, and Clay Hilliard went 7-10 from the line in overtime to push the Pilgrims to victory.
Clay Hilliard lead the Pilgrims again with a game high of 23 points. Jake Reichard added 12 points all in the first half. He came down hard on his head attempting to grab a rebound late in the first half and left the game. He tried coming back in the second half but was unable to go long. Cole Filson added 10 points. Adam Hunter had two huge three pointers late in the game and ended with seven points. Barron finished with six rebounds and five assists. Filson had four rebounds and five assists. Kendall Himes hauled down five rebounds while Ivan Winkle added four rebounds and three assists.
The win moves the Pilgrims to 2-0 in the NLC and 8-3 overall. The Pilgrims host Tippecanoe Valley Saturday night at The Rock. Tip off for the JV contest is set for 6:15.
The JV Pilgrims kept their winning ways going Friday night over Memorial 66-54. The Pilgrims got off to a great start leading at halftime 34-16. The Pilgrims held on for the victory in the second half as Memorial outscored the Pilgrims 39-32.
Adam Hunter only played 12 minutes in the game but scored 24 points. Brady Hissong added 18 points. Dylan Gamble pulled down eight rebounds.
With the win, the JV Pilgrims moved their record to 2-0 in the NLC and 10-1 overall.